In the published article, there was an error in Figures 3E, 4E as published. The images of Vehicle in Figure 3E and TEOA + GSH in Figure 4E were incorrect. The corrected Figures 3E, 4E and its caption appear below.
FIGURE 3
TEOA affected the expression of apoptosis-related protein in OCI-LY10 cells. (A) Diffuse large B-cell lymphoma (DLBCL) cells were exposed to various concentrations of TEOA for 12 h. The expression of the following apoptosis-related proteins was determined by western blot: cleaved PARP, caspase-3, and Bcl-2 family members Bcl-2, Bad, and Bax; β-actin was used as a loading control. (B) The quantitation of cleaved PARP, caspase-3, Bcl-2, Bad, and Bax were shown. ∗p < 0.05; ∗∗p < 0.01. (C) OCI-LY10 cells were treated with different doses of TEOA for 12 h. The expression of P53, P21, P27, and g-H2AX protein was determined by western blot; β-actin was used as a loading control. (D) The quantitation of P53, P21, P27, and γ-H2AX. Data were presented as mean ± SD. ∗p < 0.05; ∗∗p < 0.01. (E) OCI-LY10 cells were treated with 25 μM TEOA for 12 h and stained with γ-H2AX (1:200) antibody. DAPI was used for nucleus staining. Images were acquired with the confocal laser scanning microscopy.
FIGURE 4
| TEOA increased the production of cellular ROS and promoted apoptosis. (A) OCI-LY10 cells were exposed to different concentrations of TEOA for 12 h, then treated cells were stained with DCF-DA for 30 min, cellular ROS levels were determined by flow cytometry. (B) Quantitative analysis of the cellular ROS, ∗p < 0.05. OCI-LY10 and OCI-LY3 cells were treated with TEOA for 12 h in the presence or absence of NAC and GSH, cell death was determined by CCK8 assay (C,D) and PI staining (E). (F) Flow cytometry was used to detect apoptosis in DLBCL cells exposed to TEOA with or without NAC treatment. (G) The proportion of apoptotic cells was shown on the right, ∗p < 0.01.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
TEOA, diffuse large B-cell lymphoma, DNA damage, reactive oxygen species, p38 MAPK
Citation
Yu X, Wang X, Wang X, Zhou Y, Li Y, Wang A, Wang T, An Y, Sun W, Du J, Tong X and Wang Y (2022) Corrigendum: TEOA inhibits proliferation and induces DNA damage of diffuse large B-cell lymphoma cells through activation of the ROS-dependent p38 MAPK signaling pathway. Front. Pharmacol. 13:973989. doi: 10.3389/fphar.2022.973989
Received
20 June 2022
Accepted
01 July 2022
Published
12 August 2022
Volume
13 - 2022
Edited and reviewed by
Xu Zhang, Jiangsu University, China
Updates
Copyright
© 2022 Yu, Wang, Wang, Zhou, Li, Wang, Wang, An, Sun, Du, Tong and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ying Wang, nancywangying@163.com; Jing Du, dujing1@hmc.edu.cn; Xiangmin Tong, tongxiangmin@163.com
†These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.